Your browser does not seem to support JavaScript. As a result, your viewing experience will be diminished, and you have been placed in read-only mode.
Please download a browser that supports JavaScript, or enable it if it's disabled (i.e. NoScript).
为更好用户体验，请点击屏幕右上角 [ ··· ],在浏览器里打开
《经济通通讯社30日专讯》远大医药(00512)公布,创新液体栓塞剂Lava在美国正式商业化,该为美国首款也是唯一一款获得美国食品药物管理局批准用于治疗外周血管动脉出血的创新液体栓塞剂。
此外,该集团指,另一款适用于脑动静脉畸形的术前栓塞的产品Kona已向美国食品药物管理局递交上市前审批申请,预计将于年末获批上市。(wh)
尚无回复
